Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2000 1
2003 2
2004 1
2005 1
2006 1
2007 1
2008 4
2009 3
2010 5
2011 3
2012 1
2013 4
2014 5
2015 5
2016 10
2017 3
2018 8
2019 10
2020 12
2021 13
2022 10
2023 5
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

97 results

Results by year

Filters applied: . Clear all
The following terms were ignored: %, %, %
The following terms were not found in PubMed: 20Fakhrudin, 20Vasanwala
Page 1
Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia.
DiNardo CD, Lachowiez CA, Takahashi K, Loghavi S, Xiao L, Kadia T, Daver N, Adeoti M, Short NJ, Sasaki K, Wang S, Borthakur G, Issa G, Maiti A, Alvarado Y, Pemmaraju N, Montalban Bravo G, Masarova L, Yilmaz M, Jain N, Andreeff M, Jabbour E, Garcia-Manero G, Kornblau S, Ravandi F, Konopleva MY, Kantarjian HM. DiNardo CD, et al. J Clin Oncol. 2021 Sep 1;39(25):2768-2778. doi: 10.1200/JCO.20.03736. Epub 2021 May 27. J Clin Oncol. 2021. PMID: 34043428 Free PMC article. Clinical Trial.
RESULTS: Sixty-eight patients have enrolled to date (PIB, 16; PIIA, 29; PIIB, 23). Median age was 46 years (range, 20-73). Grade 3 and 4 adverse events occurring in 10% of patients included febrile neutropenia (50%), bacteremia (35%), pneumonia (28%), and sepsis (12%). ...
RESULTS: Sixty-eight patients have enrolled to date (PIB, 16; PIIA, 29; PIIB, 23). Median age was 46 years (range, 20-73). Grade 3 an …
Long-term cannabidiol treatment for seizures in patients with tuberous sclerosis complex: An open-label extension trial.
Thiele EA, Bebin EM, Filloux F, Kwan P, Loftus R, Sahebkar F, Sparagana S, Wheless J. Thiele EA, et al. Epilepsia. 2022 Feb;63(2):426-439. doi: 10.1111/epi.17150. Epub 2021 Dec 27. Epilepsia. 2022. PMID: 34957550 Free PMC article. Clinical Trial.
At the time of analysis, 5% of patients had completed treatment, 20% had withdrawn, and 75% were ongoing. One-year retention rate was 79%. ...Most common AEs were diarrhea (42%), seizure (22%), and decreased appetite (20%). AEs led to permanent discontinuation in 6% …
At the time of analysis, 5% of patients had completed treatment, 20% had withdrawn, and 75% were ongoing. One-year retention rate was …
ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial.
Wrangle JM, Velcheti V, Patel MR, Garrett-Mayer E, Hill EG, Ravenel JG, Miller JS, Farhad M, Anderton K, Lindsey K, Taffaro-Neskey M, Sherman C, Suriano S, Swiderska-Syn M, Sion A, Harris J, Edwards AR, Rytlewski JA, Sanders CM, Yusko EC, Robinson MD, Krieg C, Redmond WL, Egan JO, Rhode PR, Jeng EK, Rock AD, Wong HC, Rubinstein MP. Wrangle JM, et al. Lancet Oncol. 2018 May;19(5):694-704. doi: 10.1016/S1470-2045(18)30148-7. Epub 2018 Apr 5. Lancet Oncol. 2018. PMID: 29628312 Free PMC article. Clinical Trial.
ALT-803 was administered at one of four escalating dose concentrations: 6, 10, 15, or 20 mug/kg. The primary endpoint was to define safety and tolerability and to establish a recommended phase 2 dose of ALT-803 in combination with nivolumab. ...No grade 4 or 5 adverse even …
ALT-803 was administered at one of four escalating dose concentrations: 6, 10, 15, or 20 mug/kg. The primary endpoint was to define s …
How microRNAs affect the PD-L1 and its synthetic pathway in cancer.
Danbaran GR, Aslani S, Sharafkandi N, Hemmatzadeh M, Hosseinzadeh R, Azizi G, Jadidi-Niaragh F, Babaie F, Mohammadi H. Danbaran GR, et al. Int Immunopharmacol. 2020 Jul;84:106594. doi: 10.1016/j.intimp.2020.106594. Epub 2020 May 12. Int Immunopharmacol. 2020. PMID: 32416456 Review.
MicroRNAs (miRNAs) are endogenous molecules that are classified as small non-coding RNA with approximately 20-22 nucleotides (nt) length. The function of miRNAs is based on complementary interactions with target mRNA via matching completely or incompletely. ...
MicroRNAs (miRNAs) are endogenous molecules that are classified as small non-coding RNA with approximately 20-22 nucleotides (nt) len …
Current Diagnosis and Treatment of Painful Small Fiber Neuropathy.
Farhad K. Farhad K. Curr Neurol Neurosci Rep. 2019 Nov 26;19(12):103. doi: 10.1007/s11910-019-1020-1. Curr Neurol Neurosci Rep. 2019. PMID: 31773305 Review.
Auto-antibodies targeting neuronal antigens trisulfated heparin disaccharide (TS-HDS) and fibroblast growth factor 3 (FGFR3) are found in up to 20% of patients with SFN. Treatment of SFN includes treating the etiology and managing symptoms. ...
Auto-antibodies targeting neuronal antigens trisulfated heparin disaccharide (TS-HDS) and fibroblast growth factor 3 (FGFR3) are found in up …
Clinical Manifestations of Gastrointestinal Symptoms in COVID-19 Patients: An Integrative Review.
Abbasinia M, Hormati A, Eshagh Hossaini SK, Foroghi Ghomi SY, Zamani F, Afifian M, Ahmadpour S. Abbasinia M, et al. Gastroenterol Nurs. 2021 Jan-Feb 01;44(1):E1-E10. doi: 10.1097/SGA.0000000000000584. Gastroenterol Nurs. 2021. PMID: 33538525 Free PMC article. Review.
All reviewed articles were searched from December 11, 2019, to June 20, 2020, based on specific key words. Related findings in these articles show that the main target of COVID-19 is lung tissue, as after the virus enters the body, it mainly causes respiratory symptoms in …
All reviewed articles were searched from December 11, 2019, to June 20, 2020, based on specific key words. Related findings in these …
Correction: Solvent-driven azide-induced mononuclear discrete versus one-dimensional polymeric aromatic Möbius cadmium(II) complexes of an N6 tetradentate helical ligand.
Akbari Afkhami F, Mahmoudi G, Gurbanov AV, Zubkov FI, Qu F, Gupta A, Safin DA. Akbari Afkhami F, et al. Dalton Trans. 2022 May 24;51(20):8067. doi: 10.1039/d2dt90078e. Dalton Trans. 2022. PMID: 35574669
Correction for 'Solvent-driven azide-induced mononuclear discrete versus one-dimensional polymeric aromatic Mobius cadmium(II) complexes of an N(6) tetradentate helical ligand' by Farhad Akbari Afkhami et al., Dalton Trans., 2017, 46, 14888-14896, https://doi.org/10.1039/C …
Correction for 'Solvent-driven azide-induced mononuclear discrete versus one-dimensional polymeric aromatic Mobius cadmium(II) complexes of …
Hepatic veno-occlusive disease following sirolimus-based immune suppression.
Khimani F, McDonald GB, Shulman HM, Betts B, Locke F, Fernandez H, Anasetti C, Pidala J. Khimani F, et al. Bone Marrow Transplant. 2019 Jan;54(1):85-89. doi: 10.1038/s41409-018-0233-2. Epub 2018 Jun 12. Bone Marrow Transplant. 2019. PMID: 29895929 Clinical Trial.
A total of 58 patients were clinically diagnosed with VOD/SOS (SIR/TAC 38/308, 12.3%, vs. MTX or MMF/TAC 20/510, 3.9%). VOD/SOS diagnosed following SIR/TAC prophylaxis demonstrated later time of onset (median 39 vs. 26 days; p = 0.005), less severe hyperbilirubinemia (Bili …
A total of 58 patients were clinically diagnosed with VOD/SOS (SIR/TAC 38/308, 12.3%, vs. MTX or MMF/TAC 20/510, 3.9%). VOD/SOS diagn …
Exercise response on dose curve among class I obese young adult population.
Hassan B, Farooqui SI, Farhad A. Hassan B, et al. J Pak Med Assoc. 2022 Feb;72(2):216-221. doi: 10.47391/JPMA.109. J Pak Med Assoc. 2022. PMID: 35320164 Free article. Clinical Trial.
METHODS: The randomised study was conducted from December 1, 2019, to April 31, 2020, at Ziauddin Hospital, Karachi, and comprised individuals of either gender aged 20-40 years with class-I obesity. All participants were initially screened using a physical activity and rea …
METHODS: The randomised study was conducted from December 1, 2019, to April 31, 2020, at Ziauddin Hospital, Karachi, and comprised individua …
Assessment of the mechanical forces applied during eye rubbing.
Hafezi F, Hafezi NL, Pajic B, Gilardoni F, Randleman JB, Gomes JAP, Kollros L, Hillen M, Torres-Netto EA. Hafezi F, et al. BMC Ophthalmol. 2020 Jul 22;20(1):301. doi: 10.1186/s12886-020-01551-5. BMC Ophthalmol. 2020. PMID: 32698803 Free PMC article.
97 results